CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP

10th  July 2026 – CHOSA Oncology AB ("CHOSA" or the "Company") today announces the appointment of Bill Cronin to support the Company's commercial expansion in the United States. Bill Cronin will lead CHOSA's US business development and commercialization activities as the Company advances the market introduction of Platin-DRP® in the world's largest oncology diagnostics market. Bill Cronin will be based in Kendall Square, Boston the most important oncology centre in the US.

The appointment follows CHOSA's recent clinical progress, including the presentation of data from the ETOP/EORTC SPLENDOUR study, where Platin-DRP® identified patients with advanced lung cancer achieving a median overall survival of 16.9 months compared with 5.6 months for patients predicted not to benefit from platinum therapy. These results further support CHOSA's US commercialization strategy for Platin-DRP®.

Bill Cronin brings more than two decades of executive leadership and commercial experience from the US life science, especially the oncology field and medical technology sectors. Most notably, he served as Chief Executive Officer of Dignitana AB from 2015 to 2022, where he led the commercialization of the Company's FDA-cleared DigniCap® Scalp Cooling System, used together with chemotherapy in breast cancer, in the United States. Under his leadership, Swedish Dignitana established its US commercial organization, expanded adoption at leading cancer centres, and transformed the United States into the Company's primary commercial market. Dignitana was acquired by the British company Paxman Coolers – a process where Bill was deeply involved.

At CHOSA, Bill Cronin will focus on executing the Company's US commercialization strategy, including developing relationships with pharmaceutical companies, academic cancer centres, clinical laboratories, strategic partners, and key opinion leaders. He will also support the planned Research Use Only (RUO) launch of Platin-DRP® and help position the Company for future commercial expansion.

Ingrid Atteryd Heiman, Chairman of CHOSA Oncology, commented:

"Having worked closely with Bill for many years during the successful expansion of Dignitana in the United States, I have first-hand experience of his ability to transform innovative Scandinavian healthcare technologies into commercially successful businesses in the US market. His leadership, strategic mindset, and extensive network will be invaluable assets as CHOSA enters its next phase of growth. We are delighted to welcome Bill to the CHOSA team."

Peter Buhl Jensen, CEO of CHOSA Oncology, added:

"The United States represents our most important commercial market, and Bill's unique experience in building US operations for a Swedish oncology company aligns perfectly with CHOSA's strategy. His commercial expertise and understanding of the US oncology ecosystem will significantly strengthen our ability to establish Platin-DRP® in the market."

Bill Cronin commented:

“Having helped bring a number of Scandinavian life science innovations to the US market, I find Platin-DRP® one of the most exciting I've worked with yet. The CHOSA team has built something that can genuinely change how oncologists decide if platinum therapy is the right choice for their patients. I'm grateful for the chance to help lead that effort, and I'm looking forward to working alongside the really impressive team CHOSA has put together to get it there.”

The appointment follows CHOSA's recent establishment of its US presence in Boston and represents another important milestone in building the commercial organization needed to support the long-term growth and commercialization of Platin-DRP® in the United States.

For more information please contact:

Peter Buhl Jensen, CEO

peter@chosa.bio

+ 45 21 60 89 22

About CHOSA Oncology AB
CHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression–based biomarker that predicts response to platinum-based chemotherapy. By identifying patients most likely to benefit, CHOSA aims to improve outcomes and optimize treatment selection in cancer care.

Background

Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer therapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD-1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Platin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer.

As previously announced, CHOSA is also exploring the predictive potential of Platin-DRP in those treated with carboplatin in lung cancer. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort and potentially confirm its utility across both drugs. Future research will also aim to determine whether Platin-DRP can predict the effectiveness of platinum drugs combined with PD-1/L1 inhibitors. CHOSA Oncology AB is an oncology biotechnology company led by an experienced international team with expertise in oncology, drug development, clinical trials, regulatory affairs, and business development. CHOSA intends to enter into partnership or sublicensing agreements for LiPlaCis® and the DRP®.

About Platin-DRP, a test to predict if cisplatin treatment is likely to be successful

CHOSA is focused on its Platin-DRP® drug response predictor, to which it holds worldwide rights. Platin-DRP is a validated test designed to help identify patients most likely to benefit from cis- and carboplatin treatment. Most recently, CHOSA presented results from the ETOP/EORTC SPLENDOUR study demonstrating that patients with advanced lung cancer predicted to benefit from platinum therapy achieved a median overall survival of 16.9 months compared with 5.6 months for patients predicted not to benefit.

Breast: Strong phase 2b data in metastatic breast cancer have shown that patients selected by DRP® responded better to treatment, had longer progression-free survival, and may also have achieved longer overall survival than patients identified as unlikely to respond well.

Lung: Platin-DRP has also demonstrated its ability to predict the benefit of adjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a gold standard that can improve cure rates, but doctors have not had a validated tool to identify which patients are most likely to benefit. This is where Platin-DRP may become a game changer, particularly in newer neoadjuvant settings where immunotherapy has shown high efficacy in combination with platinum doublets. Platin-DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to eliminate residual tumour cells. Patients with the 10% highest scores had a 3-year survival of 90%, whereas patients with the lowest 10% scores had a 3-year survival of only 40%¹. In 2026 CHOSA in collaboration with key opinion leaders in lung cancer showed the Platin-DRP in advanced clearly separated the patient with a sensitive cancer from a platin resistant tumor with a median survival of 16.9 months in the former group vs only 5.5 months in the latter2. 

Immunotherapy Cisplatin and carboplatin have often been shown to activate the immune system, potentially making “cold” tumours more susceptible to PD-1 inhibitors. This synergy may be important not only in lung cancer, but also in breast cancer,bladder cancer and head & neck cancer. In the growing PD-1 inhibitor market, CHOSA’s approach may offer the ability to predict whether platin can provide synergy with PD-1 inhibition, potentially creating a meaningful advantage for treatment selection and future partners.

1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume 11, Supplement 3, 106773, April 2026

DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.